Treatment with selumetinib, an MEK inhibitor, induced mesenchymal to epithelial transition, reduced the cancer stem cell population in vitro, and inhibited lung metastasis in the MDA-MB-231 xenograft model [67]. The gene discussed is MAP2K7; the disease is cancer.